Medtronic Launches Adaptive DBS in India: Real‑Time Therapy for Parkinson’s Patients

Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease.

The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern. 

Parkinson’s is a progressive neurological condition that can affect how a person moves and functions in everyday life. Over time, it may make routine activities such as walking, writing, or holding everyday objects more difficult. While movement-related challenges are often the most visible, the condition can also influence other aspects of daily living, including communication, sleep, and overall well‑being. Today, a range of treatment approaches help manage symptoms as the disease evolves. Care is typically tailored over time, with treatment pathways adjusted based on individual needs and clinical assessment by specialists.

Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers. Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management. The aDBS system uses BrainSense™ technology, which has been approved by the U.S. Food and Drug Administration (FDA).

Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery.

With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years7—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades. 

DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement. To give you relief, these signals block some of the brain messages that cause the movement symptoms of Parkinson’s.

On the occasion, Prateek Tiwari, Senior Director, Neuroscience & Specialty therapies, Medtronic India said, “We are extremely proud to introduce this advanced technology in India, where Parkinson’s disease is an increasingly significant healthcare concern. Our mission has always been to alleviate pain, restore health, and extend life, and the introduction of this system reflects our continued commitment to that mission. This milestone not only reaffirms our dedication to addressing the growing burden of Parkinson’s disease but also strengthens our leadership in bringing cutting-edge healthcare technologies to India to ultimately improve patients’ quality of life.’’

As the burden of a disease such as Parkinson’s will rise, continued investment in cutting-edge technologies will be essential to expanding access to better care, supporting clinicians with deeper insights, and ultimately improving the quality of life for patients across the country.

Patients considering deep brain stimulation (DBS) typically begin by consulting a Movement Disorder Specialist, usually a neurologist, who evaluates whether their condition may benefit from this therapy. DBS follows a coordinated, team-based approach, with patients often referred to a comprehensive DBS clinic or neurosurgery board for further assessment. If considered suitable, a Functional Neurosurgeon—specially trained to perform the procedure—works alongside the care team to implant and program the device.

All information contained herein is for general awareness purposes only, and nothing contained herein should be construed as medical advice or recommendation. Patients should consult their physician to discuss their conditions and seek relevant medical advice.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Medtronic Lunches Arctic Front™ Advanced Cardiac Cryoablation Catheter Technology for Treatment of Atrial Fibrillation in India

First patient in India treated at Max Hospital, Saket

Nearly 60 million people worldwide are affected by atrial fibrillation in India

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT) — a global leader in healthcare technology, today announced the launch of Arctic Front™ Cardiac Cryoablation Catheter System, the first and only cryoballoon catheter approved by CDSCO for treatment of atrial fibrillation (AF) in India. Dr. Balbir Singh, chairman of Cardiology, Pan Max Hospital Saket, Delhi, successfully performed the first procedure in India using the Arctic Front Cardiac Cryoablation Catheter System. Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage AF.

Nearly 60 million people worldwide are affected by AF.1 AF is an irregular heart rhythm that affects the upper chambers (atria) of the heart. A normal heart beats around 60-100 times per minute. However, in AF, the atria quiver instead of beating normally. AF can also lead to rapid heart rhythm, where the heart can beat as much as 300 times a minute or more in the atria and up to 150 times a minute or more in the lower chambers (ventricles). Additionally, AF is associated with serious complications including heart failure, stroke and increased risk of death.2-5 Indian patients with AF tend to be over a decade younger than AF patients in the western world, and two-thirds of them have either persistent or permanent AF.6 Indian AF patients also tend to have higher rates of death compared to other countries.6,7.

Medtronic Arctic Front™ advanced cardiac cryoablation catheter technology for treatment of atrial fibrillation.

Medtronic Arctic Front™ Cryoballoon catheter ablation, a minimally invasive procedure, one of the therapeutic modalities to manage atrial fibrillation.

"AF is a progressive disease, meaning over time patients can experience more frequent, and longer episodes. Cryoballoon ablation is a safe and effective treatment before or after medication therapy to control atrial fibrillation,” said Dr. Singh. “By treating patients with the most advanced, clinically relevant technology, we are better equipped to successfully manage their atrial fibrillation, thereby improving their overall quality-of-life.”

"Cryoballoon ablation is a minimally invasive procedure that offers a short recovery time and comparable safety and efficacy to standard radiofrequency therapy, but with the benefit of greater treatment efficiency. In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias,” said Madan Krishnan, vice president and managing director, Medtronic India.

Cryoablation is designed to prevent unwanted electrical signals from traveling from the pulmonary veins (large blood vessels that carry blood from the lungs to the left atrium of the heart) and spreading to the atria (the upper chambers of the heart). This is done with a technique known as pulmonary vein isolation that targets the tissue where the veins and the atria connect and prevents the spread of unwanted electrical signals. The Medtronic cryoballoon catheter was developed specifically to achieve pulmonary vein isolation. This innovative technique has been used to treat more than 1,000,000 patients in more than 80 countries with robust safety and effectiveness evidence in more than 1200 peer-reviewed articles.8

During June of this year, Medtronic received U.S. Food and Drug Administration (FDA) expanded approval in the United States for the Arctic Front™ Family of Cardiac Cryoablation Catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation (episodes that last less than seven continuous days) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy. This new indication expansion should help physicians treat AF patients earlier in the disease progression stage, which may enhance the therapeutic effectiveness.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.



Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Ireland-based MedTech Company Medtronic and Kerala Govt.’s ASAP Sign MoU to Advance Skill Development in the State

Medtronic is the Only MedTech Company to Engage in this Partnership with ASAP

Goal of Providing 12-Month Internship Opportunities for Qualified Students

Bengaluru, India – August 25, 2021 – India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT) – the world’s largest medical technology, services, and solutions company – today signed a Memorandum of Understanding (MoU) with Government of Kerala’s promoted Section 8 Company, Additional Skill Acquisition Programme Kerala (ASAP), to equip final year students with advanced skill sets and improve overall employability within the healthcare industry.

Under this program, ASAP will continue to provide and implement skill development programmes for youth through its Advanced Skill Development Centres. Simultaneously, through the Acquire Early Program, Medtronic will leverage this talent pool for its internship projects, that will see students benefit from mentorship support, constructive job experience and enhancement of their overall soft and employable skills. In addition, final year students from Tier 3 and Tier 4 institutes will undergo the Bridge Program developed by ASAP and upon successful completion, will be assessed for internship opportunities by Medtronic.

“As the largest medical technology company in the world, Medtronic has enabled skill proficiency building across biomedical engineering and multiple therapy areas, significantly contributing to the healthcare ecosystem in India. Our partnership with ASAP is one more step in that direction,” said Madan Krishnan, vice president and managing director, Medtronic India. “Through this program, we hope to extend opportunities to students to join the innovative world of medical technology and contribute to improving access to latest therapies. We firmly believe that our internship program provides an opportunity to gain valuable work experience and understand a rapidly growing and evolving med-tech industry. We remain confident that through our collaboration, we will leverage our common strengths, and continue to work with students and develop the skilling eco-system in the country, aligning with Government’s Skill India vision.”

“The very philosophy of ASAP as a skill development agency is to accentuate the employability of the youth. We look forward to leveraging this philosophy through a mutually benefitting collaboration with Medtronic and offer some unique opportunities for the youth of Kerala,” said Dr. Usha Titus, chairperson and managing director, ASAP Kerala.

Focused on providing students an immersion into the med-tech job market, Medtronic and ASAP will also partner on deploying a series of insight led webinars and guest lectures designed for third year and final year engineering students. Key Medtronic leaders will interact with young minds through these interactive sessions with the goal of providing aspiring students a peak into a career in the med-tech sector.

Additional Skill Acquisition Programme Kerala (ASAP Kerala) is a not for profit company under Government of Kerala, India, that invests in provision of industry relevant skills. Over the last 8 years, ASAP Kerala has created a unique demand-based, industry-led skill training ecosystem in the State through 121 Skill Development Centres connecting Higher Secondary Schools and Arts and Science Colleges, Advanced Skill Development Centres (ASDCs) in 90 Engineering Colleges and 45 Polytechnics institutions and 16 Community Skill Parks (CSPs) for multi-skill training.

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

India’s Next Sushruta - Medtronic India’s Case Based Competition for Resident Doctors Culminates in Grand Finale

• One of Its Kind Academic Contest Aimed at Providing Clinical Exposure To Nurture Budding Surgeons in India
  
  
• Three Winners Arising from Over 1300+ Entries Across 80 Cities Will Get a Chance To Take Part in an International Clinical Observership at a Medtronic Innovation Center .

 ​

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE: MDT), concluded the grand finale of India’s Next Sushruta (INS), a case study competition targeted towards postgraduates and super-specialty students in the field of surgery. The concluding round saw finalists competing for the top three spots with a chance to take part in an international clinical observership at a Medtronic Innovation center. The finale saw Dr. Usha H., MCh Surgical Oncology from Kidwai memorial institute of oncology, Bangalore win over the jury with her presentation to clinch the title of India’s Next Sushruta. Dr. Souvik Paul, DNB Surgical Gastroenterology from BLK Superspeciality Hospital, New Delhi was adjudged the 1st runner up, while Dr. Nitesh Kumar, MS Urology from Osmania Medical College, Hyderabad took the 2nd runner up place.

Named after the father of early surgery, Sushruta, India’s Next Sushruta is a one of a kind industry-academia program in the med-tech space in India. The competition saw participation from across specialties including general surgery, gastro and oncology. The multi-stage academic contest was administered in partnership with Docplexus, who executed the program spanning 80 cities and conducted quantitative quizzes and abstract submissions on their platform.

“At Medtronic, we are committed to transforming healthcare, but we know we can’t do it alone. As global healthcare evolves, it is our responsibility as partners to evolve with it. India’s Next Sushruta is a unique opportunity for young doctors from multiple medical schools and disciplines to come together to present their views to address health issues plaguing the country and gives these medical students to gain skills and experience thinking outside the box while continuing their education,” said Madan Krishnan, vice president & managing director, India Medtronic Pvt. Ltd. “Through this program we hope to address prevalent capacity and awareness barriers along with increasing patient access to various therapies in the future. We are thrilled with the opportunity to engage with young resident doctors and Heads of Departments of these medical institutes.”

The grand finale of INS involved 20-minute case presentations by the top ten finalists judged by a panel comprising of experts from major institutes: 

• Dr. Avanish Saklani, associate professor robotic lead colorectal, Tata Memorial Center, Mumbai
• Dr. Abhay Dalvi, professor & unit head, Dept. of Surgery, KEM Hospital, Mumbai 
• Dr. Anil Aggarwal, director, professor & head, Dept. of Gastrointestinal Surgery, GB Pant Hospital, Delhi 
• Dr. S Sudhindran, professor & chief transplant surgeon, Dept. of Gastrointestinal Surgery, Amrita Hospital, Kochi 
• Dr. SVS Deo, professor & head, Surgical Oncology, AIIMS Delhi 
• Dr. Madhabananda Kar, professor & head, Dept. of Surgical Oncology, AIIMS Bhubaneswar 

Raising adequate awareness about disease and therapy areas coupled with skill development to achieve technology adoption is the long-term objective of INS. Consequently, from among the top 10 finalists, the final 7 have been selected to participate in proctorship programs in India.

Medtronic Introduces Mazor X Stealth Edition for Robotic-Assisted Spine Surgery in India

• First Patient in India Treated at Indian Spinal Injuries Centre, New Delhi


• Surgical Robotics Market in India is Predicted to Grow Remarkably


• Mazor X Stealth Edition™ Will Enable Doctors to Plan Their Surgery, Provide Assistance to Execute the Plan Precisely and Visualize the Progress in Real-Time

​India Medtronic Private Limited, wholly-owned subsidiary of Medtronic plc (NYSE:MDT), today announced the launch of the Mazor X Stealth Edition™ that offers a fully-integrated procedural solution for surgical planning, workflow, execution and confirmation of spine surgeries. Surgeons at Indian Spinal Injuries Centre, New Delhi, have successfully performed the first minimally invasive spine surgery in India using the Mazor X Stealth Edition™ Robotic-Assisted Spine Surgery System.

The global surgical robotics market has a vast potential, and it is expected to grow to US$9.3 billion by 2025 from US$4.9 billion back in 2016 with a CAGR of 11.4%1. In India, with a rapidly growing senior population, the spine surgery rate is expected to rise. The Surgical Robotics Market in India is predicted to witness a remarkable increase from US$129.9 million in 2016 to US$372.5 million in 2025, growing at a CAGR of 19.2%.1

"Minimally-invasive spinal procedures with their smaller incisions can pose a challenge to surgeons due to the limited view of the patient's anatomy. The combination of robotics and navigation provides an opportunity for not only procedural benefits but also the potential for clinical efficiency and improvement in patient outcomes,” said Dr. H.S. Chhabra, medical director, Indian Spinal Injuries Centre, New Delhi. “We can now perform the same spinal surgery with precision as planned along with the ability to confirm through navigation that the implant is going in the location as it was intended to.”

"We believe technology has the power to improve lives. That's why we are continually innovating novel products and procedural solutions in the area of minimally invasive therapies; to improve the quality of life for all patients. We are bringing a myriad of new technologies to India to improve access to the best treatment options for patients,” said Madan Krishnan, vice president and managing director, India Medtronic Pvt Ltd. “This year being the 40th year for Medtronic in India, we are happy to demonstrate our commitment to transforming healthcare in India with renewed vigour by launching the Mazor X Stealth Edition™ Robotic-assisted Spine Surgery System."

Co-developed between Medtronic and the recently acquired Mazor Robotics, the Mazor X Stealth Edition™ seamlessly incorporates Stealth™ software technology into the Mazor X robotic-assisted surgery platform. It is a revolutionary new technology that uses cutting-edge software to plan the surgical procedure, then uses a robotic arm to guide implants and instruments through the steps of the surgical process with precision, while simultaneously using real-time imaging feedback to ensure the plan is being carried out as desired. The Mazor X Stealth Edition™ operates on three principals: first, the surgeon can plan and visualize the surgery beforehand to study multiple levels and the entire process; second, the robotic guidance system will be an extension of the doctor during the process and is intended to enable execution with precision; and third, the doctor can visualize progress in real-time.
About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References:
1 https://www.analyticsinsight.net/analytics-insight-estimates-indian-surgical-robotics-market-at-us129-million-by-2025/

~ BusinessWire India